DUEL ANTIPLATILETE ADVANTAGES
News that has been officially released to the public by reputable sources while using Gemini AI.
The DAPT-MVD trial, published in the New England Journal of Medicine, indicates that extending dual antiplatelet therapy for an extra 12 months in patients with severe, multivessel coronary artery disease reduces risks of cardiovascular death, heart attack, and stroke without increasing major bleeding. Additionally, research suggests that while genetics influence CAD risk, lifestyle interventions and medical therapies can effectively mitigate this risk, regardless of familial history. For more details, read the full study at New England Journal of Medicine. [1, 2, 3, 4]
SOURCE
No comments